Status: Not yet recruiting
A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer
This is a first-in-human Phase 1 study of DEM301 in adults with previously treated advanced metastatic colorectal cancer. DEM301 is an investigational antibody-drug conjugate. The study will evaluate the safety and tolerability of DEM301, identify doses for further study, and assess how the drug behaves in the body and whether it shows signs of activity against the cancer.
Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: DEM BioPharma, Inc.Updated: Sep 9, 2026
Eligibility criteria
Age ≥18 years. [+10]
Prior treatment with certain antibody-drug conjugates, as defined in the protoco... [+10]